# Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

> **NCT04094142** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 66 (actual)

## Conditions studied

- Non-hodgkin Lymphoma,B Cell

## Interventions

- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT04094142
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-09
- **Primary completion:** 2022-05-15
- **Final completion:** 2022-05-15
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04094142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04094142, "Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04094142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*